<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Slovenia_TheSwitchDesignedTALregulators"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Slovenia/TheSwitchDesignedTALregulators">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Slovenia/TheSwitchDesignedTALregulators&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Slovenia/TheSwitchDesignedTALregulators&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Slovenia/TheSwitchDesignedTALregulators&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Slovenia/TheSwitchDesignedTALregulators" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Slovenia/TheSwitchDesignedTALregulators</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2012.igem.org</H3><DIV id="mainmenu"><DIV id="cssmenu"><UL><LI><A href="https://2012.igem.org/Team:Slovenia"><SPAN>Home</SPAN></A></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/Idea"><SPAN>Idea</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/IdeaBioTherapy"><SPAN>Biological therapy</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/IdeaChallenge"><SPAN>Challenge</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Idea"><SPAN>Solution</SPAN></A></LI></UL><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/TheSwitch"><SPAN>The switch</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/TheSwitch"><SPAN>Overview</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators"><SPAN>Designed TAL regulators</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch"><SPAN>Mutual repressor switch</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Positive feedback loop switch</SPAN></TD></TR></TBODY></TABLE></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchControls';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Controls</SPAN></TD></TR></TBODY></TABLE></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/SafetyMechanisms"><SPAN>Safety mechanisms</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SafetyMechanisms"><SPAN>Overview</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag"><SPAN>Escape tag</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination"><SPAN>Termination</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Microcapsule degradation</SPAN></TD></TR></TBODY></TABLE></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/Implementation"><SPAN>Implementation</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Implementation"><SPAN>Overview</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC"><SPAN>Hepatitis C</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease"><SPAN>Ischaemic heart disease</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ImplementationImpact';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Impact</SPAN></TD></TR></TBODY></TABLE></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/Modeling"><SPAN>Modeling</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Modeling"><SPAN>Overview</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingPK';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Pharmacokinetics</SPAN></TD></TR></TBODY></TABLE></LI><LI><A href="https://2012.igem.org/Team:Slovenia/ModelingMethods"><SPAN>Modeling methods</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch"><SPAN>Mutual repressor switch</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch"><SPAN>Positive feedback loop switch</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Experimental model</SPAN></TD></TR></TBODY></TABLE></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Interactive simulations</SPAN></TD></TR></TBODY></TABLE></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Parts"><SPAN>Parts</SPAN></A></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/Notebook"><SPAN>Notebook</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Notebook"><SPAN>Experimental methods</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/NotebookLablog';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Lablog</SPAN></TD></TR></TBODY></TABLE></LI><LI><A href="https://2012.igem.org/Team:Slovenia/NotebookLabSafety"><SPAN>Lab safety</SPAN></A></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/Society"><SPAN>Society</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Society"><SPAN>Human practice</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyScientists"><SPAN>Scientists</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyMedicalDoctors"><SPAN>Physicians</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyEthics"><SPAN>Ethics, safety and regulations</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyPatients"><SPAN>Patients</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyMedia"><SPAN>Journalists and general public</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyOutreach"><SPAN>Outreach</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/SocietyQuestionnaire"><SPAN>Questionnaire</SPAN></A></LI><LI class="has-sub "><A href="https://2012.igem.org/Team:Slovenia/Team"><SPAN>Team</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/Team"><SPAN>Team members</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/TeamAttributions"><SPAN>Attributions</SPAN></A></LI><LI><TABLE onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TeamCollaborations';" class="newtable"><TBODY><TR class="newtable"><TD class="newtable"><SPAN>Collaborations</SPAN></TD></TR></TBODY></TABLE></LI><LI><A href="https://2012.igem.org/Team:Slovenia/TeamGallery"><SPAN>Gallery</SPAN></A></LI><LI><A href="https://2012.igem.org/Team:Slovenia/TeamSponsors"><SPAN>Sponsors</SPAN></A></LI></DIV></DIV><DIV id="main"><H1> TAL-based transcriptional regulators</H1><TABLE class="summary"><TBODY><TR class="summary"><TD class="summary"><P>We created several <B>TAL repressors</B> by fusions of the <B>KRAB repression domain</B> to different positions relative tothe TAL DNA-binding domain and <B>reporter plasmids with their respective binding sites (operators). </B></P><P>We created <B>several TAL activator constructs</B> by C-terminal fusion of the <B>VP16 domain with TAL DNA-binding domains</B> and reporter plasmids with their respective operators. </P><P>We <B>improved and characterized the NicTAL DNA-binding domain</B> (deposited by the iGEM2010 team Slovenia) by adding the missing subdomain of the protein and created a designed repressor and activator. </P><P>TAL:KRAB fusions exhibited over <B>90% repression</B> of reporter gene expression <B>regardless of the position of the KRAB domain. </B></P><P><B>Minimal promoters used for construction of reporter plasmids showed no or minimal leakiness</B> and were <B>activated over 1500-fold</B> by TAL:VP16 fusions. </P><P><B><FONT color="red">(NEW)</FONT></B> Our experimental results on designed TAL regulators provided parameters for the quantitative deterministic modeling of bistable switches. </P></TD></TR></TBODY></TABLE><H2>Designed TAL transcriptional regulators </H2><P>For the past two decades, engineered zinc finger proteins have been extensively used for targeting specific DNA sequences. However, in spite of the many years of technological development, engineered zinc finger proteins are not able to target every desired DNA sequence due to the impact of neighboring fingers on the recognition of base pairs. Recently DNA-binding proteins with a simpler DNA recognition code were discovered. <B>Transcription activator like <A href="https://2012.igem.org/Team:Slovenia/Parts#TALeffectors">(TAL) effectors</A></B> are bacterial plant pathogen transcription factors that bind to DNA by <B>recognizing a specific DNA sequence in which each base pair binds to a single tandem repeat in the TAL DNA-binding domain</B> (Figure 1A). A tandem TAL repeat contains 33 to 35 amino acids, where the 12th and the 13th amino acid, called a “repeat variable diresidue” (RVD), are responsible for specific interactions with the corresponding base pair (Scholze and Boch, 2011). As evident from the crystal structure of TAL effectors (Mak et al., 2012; Deng et al., 2012; Figure 1B), all TAL repeats have almost identical conformations, differing only in the RVDs. This <B>modularity</B> of TAL effector binding domains therefore makes them a <B>perfect tool</B> to target specific DNA sequences. </P><TABLE class="invisible" style="width:70%;"><TBODY class="invisible"><TR class="invisible"><TD class="invisible"><P><B>Figure 1.The structure of TAL effectors. </B> (A) Schematic representation of TAL effector structure and its DNA-binding domain (red), containing multiple 34 aminoacid tandem repeats with RVDs at the 12th and 13th residue (Scholze and Boch, 2011). (B) 3D structure of a TAL effector. </P></TD></TR></TBODY></TABLE><P><B>Figure 2.Models of 3D structures of TAL DNA-binding domains fused with the KRAB repression domain (A) and VP16 activation domain (B). </B></P><P>TAL effectors have mostly been used as a tool for plant or mammalian genome editing. The basic idea is the same as with zinc finger nucleases, with TALs replacing zinc fingers as the specific DNA-binding domain (Miller et al., 2010). Several groups (Miller et al., 2011; Zhang et al, 2011; Garg et al., 2012; Cong et al., 2012) have also designed TAL effectors for <B>specific gene activation,</B> by fusing them with either <B>the Herpes simplex virus VP16 activation domain</B> or its <B>tetrameric derivative VP64</B> (Figure 2). After we already initiated the iGEM 2012 project, <B>TAL repressors</B> were reported by Garg et al., and Cong et al.,who created TAL effectors fused with <B>the KRAB or SID transcriptional repression domain. </B></P><H2>Results</H2><P><TABLE class="inliner" style="width:55%; margin-top:25px; margin-bottom:100px;"><TBODY class="inliner"><TR class="normal"><TD class="inliner" style="text-align:justify;"><B>Figure 3. Schematic representation of tested plasmids. </B> (A) TAL repressors; fusions of TAL DNA-binding domains with the KRAB repression domain. (B) TAL activator; fusion of TAL DNA-binding domain with the VP16 activation domain. Expression of TAL effectors is under the control of constitutive CMV promoter. (C) Reporter plasmids used to test efficiency of TAL regulators. TAL DNA-binding sites are placed upstream of either a CMV promoter (repression) or a minimal promoter (activation), driving the expression of reporter genes (firefly luciferase or mCitrine).
</TD></TR></TBODY></TABLE></P><P>The TAL transcriptional activators and repressors were basic tools in our iGEM project. We designed and characterized three functional <A href="https://2012.igem.org/Team:Slovenia/Parts#TALs">TAL regulators</A> (<A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782004">TALA</A>, <A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782006">TALB</A> and <A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782005">TALD</A>) by fusing TAL DNA-binding domains (Sander et al., 2011) with the VP16 activation domain (Figure 3B) or a KRAB repression domain (Figure 3A), as shown on Figure 2. To assess the activity of designed TAL regulators, we also designed <A href="https://2012.igem.org/Team:Slovenia/Parts#reporters">reporter plasmids</A>, which contain several repeats of TAL binding sites upstream of either a CMV promoter (repression) or a minimal promoter (activation) (Figure 3C). </P><P>In addition to the synthesis of new TAL effector-based parts and their characterization, our team also improved a part which was deposited in the Registry by the Slovenian iGEM2010 team. They synthesized a TAL effector, named <A href="http://partsregistry.org/Part:BBa_K323214">NicTAL</A>, which did not work as expected in mammalian cells. We discovered that a subdomain next to the DNA-binding domain was missing, because the requirements for the functional TAL binding domains have not been known two years ago. We linked the missing subdomain to the DNA-binding domain of NicTAL from the Registry. Additionally we prepared chimeric proteins of the <A href="http://partsregistry.org/Part:BBa_K782007">NicTAL-DNA binding domain</A> and KRAB or VP16 domains, generating another repressor and activator pair and demonstrated the newly acquired functionality of the NicTAL-based regulators. </P><H3>Designed repressors</H3><P>We designed and tested three different variants of TAL DNA-binding domain fusions with the KRAB repression domain. KRAB was placed either on both termini or on the N- or C-terminus of the TAL DNA-binding domain (Figure 3A). All tested constructs offour different TAL domains exhibited <B>over 90% repression of the reporter plasmid</B> (with the exception of <A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782009">KRAB:TALD</A>). We expected to observe a difference in repression due to potential clustering of KRAB-binding proteins, but no significant variation between constructs was noticeable. Our conclusion is that <B>the position of the effector (regulator) domain on either the N- or C-terminus or both does not influence the binding and repression ability of the designed TAL repressors. </B> All further experiments were performed with <A href="https://2012.igem.org/Team:Slovenia/Parts#TALeffectors">TAL:KRAB</A> fusions. </P><TABLE class="inliner" style="width:40%; text-align:justify; float:left;"><TBODY class="inliner"><TR class="inliner"><TD class="inliner"><B>Figure 4. Schematic representation of repression experiments. </B> (A) In the absence of a TAL repressor, the reporter gene is constitutively expressed. (B) When a TAL repressor is expressed, it binds to its respective DNA-binding site upstream of the CMV promoter and represses transcription of the reporter gene through KRAB domain-mediated transcriptional silencing. 
</TD></TR></TBODY></TABLE><TABLE class="inliner" style="width:60%;  text-align:justify;"><TBODY class="inliner"><TR class="inliner"><TD class="inliner"><B>Figure 5. TAL repressors potently inhibit expression of reporter genes. </B> HEK293T cells were cotransfected with TAL repressors under the control of a CMV promoter (50 ng), and with a firefly luciferase reporter plasmid (Figure 3C) containing 10 DNA-binding sites for the designated TAL repressor upstream the CMV promoter (10 ng). Along with the tested constructs we transfected cells with 5 ng of Renilla luciferase under the HSV-TK promoter as transfection control. Luciferase activity was measured 3 days post-transfection. All experiments were executed in 3 biological replicates and repeated more than 3 times with similar results. 
</TD></TR></TBODY></TABLE><P>Results show that the previously non-functional NicTAL10:KRAB fusion (NicTAL DNA-binding domain constructed by the iGEM2010 team Slovenia) acquired functionality by the N-terminal addition of a subdomain to the TAL DNA-binding domain (Figure 5). An <B>excellent repression ability of <A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782011">NicTAL12:KRAB</A> (the improved version by the 2012 team) </B> was observed. The NicTAL12 repressor was further characterized by testing the effect of a different number of binding sites upstream of the PCMV promoter on the inhibition of reporter expression. Results presented in Figure 6 show that the <B>maximal effect of the bound TAL regulator plateaus at 7 or more copies of binding sites per operator. </B> In all further experiments we used plasmids with 10 copies of TAL DNA-binding sites. </P><TABLE class="inliner" style="width:100%; text-align:justify;"><TBODY class="inliner"><TR class="inliner"><TD class="inliner"><B>Figure 6. Number of DNA-binding sites specific for NicTAL12:KRAB repressor dictates the efficiency of inhibition of reporter expression. </B> HEK293T cells were cotransfected with NicTAL repressors under CMV promoter (50 ng), and firefly luciferase reporter plasmids (Figure 3C) with different number of NicTAL binding sites upstream of the CMV promoter (100 ng). Luciferase activity was measured 3 days post-transfection. The experiment was executed in threebiological replicates and repeated three times with similar results. 
</TD></TR></TBODY></TABLE><H3>Designed activators</H3><P><TABLE class="inliner" style="width:40%; float:left; text-align:justify;"><TBODY class="inliner"><TR class="inliner"><TD class="inliner"><B>Figure 7. Schematic representation of activation experiments. </B> (A) In the absence of a TAL activator, there is no expression of the reporter gene. (B) When TAL activator is present, it binds to its DNA-binding site upstream of the minimal promoter and activates transcription of the reporter gene. 
</TD></TR></TBODY></TABLE></P><P>Due to the mechanism of action of the VP16 domain and our previous results with TAL:KRAB repressors (Figure 5, position of the effector domain does not influence repression); we decided to test only the C-terminal variant of the <A href="https://2012.igem.org/Team:Slovenia/Parts#TALactivators">TAL:VP16 fusion</A> (Figure 3A). Both tested TAL activators exhibited <B>over 1500-fold activation</B> of the mCitrine reporter at reporter to activator ratios 1:2. In addition, we confirmed that <B>the minimal promoter used to drive the expression of the reporter gene shows no (or minimal) leakiness</B> - this trait makes this promoter an excellent element for genetic systems, where tight transcriptional regulation is needed. </P><TABLE class="invisible" style="width:90%;  text-align:justify;"><TBODY class="invisible"><TR class="invisible"><TD class="invisible"><B>Figure 8. TAL activators strongly activate the reporter gene expression. </B> The number of DNA-binding sites specific for NicTAL12:KRAB repressor dictates the efficiency of inhibition of reporter expression. HEK293T cells were cotransfected with TAL activator constructs under the CMV promoter (different quantities, for ratios see the x axis), and mCitrine reporter plasmids (Figure 3B) containing 10 copies of binding sites for the designated TAL activator upstream of a minimal promoter (50 ng). Along with the tested constructs we transfected cells with 20 ng of mCherry fluorescent protein under the CMV promoter as transfection control. Fluorescence was measured three days post-transfection. All experiments were executed in 3 biological replicates and repeated three times with similar results. 
</TD></TR></TBODY></TABLE><H3><B><FONT color="red">(NEW)</FONT></B> TAL regulators are functional and nontoxic for multicellular animals</H3><P>In collaboration with iGEM <A href="https://2012.igem.org/Team:Evry/FrenchFrog">team Evry</A> we tested the ability of TAL regulators to function in cells of amphibians. We selected a reporter plasmid with mCitrine under the operator for TAL VP16 activator in the presence and absence of the TAL activator. Only cells of animals transfected with both plasmids exhibited fluorescence, which was absent in cells transfected only with reporter. It is exciting to see fluorescent tadpoles that were transfected with functional TAL activator and a reporter, which demonstrates that TAL activator is not deleterious for the development of the animal.</P><TABLE class="invisible" style="width:90%;  text-align:justify;"><TBODY class="invisible"><TR class="invisible"><TD class="invisible"><B>Figure 9. TAL-based transcriptional activator is active in a multicellular organism.</B> Reporter plasmid (10x[TALA] pMIN mCitrine, <A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782029">BBa_K782029</A>) was injected into <I>Xenopus laevis</I> embryo (2.3 nl of plasmid at concentration 100 ng/µl) in the presence or absence of a plasmid with TAL activator (pCMV-TALAVP16, <A href="http://partsregistry.org/wiki/index.php?title=Part:BBa_K782065">BBa_K782065</A>). Fluorescence of mCitrin and rhodamine, which was used with plasmid for injection control was observed 1 and 3 days after introduction of plasmids under the microscope as described <A href="https://2012.igem.org/Team:Evry/Protocols">https://2012.igem.org/Team:Evry/Protocols</A>.
</TD></TR></TBODY></TABLE><P>Our joint results obtained in collaboration with <A href="https://2012.igem.org/Team:Evry">Evry team</A> (thank you froggies) thus demonstrate that TAL-based logic can be used also in the whole animal, which could be used as an excellent model to study complex synthetic regulatory devices in the multicellular environment.</P><H2 style="color:grey;">References</H2><P style="color:grey;">
Deng, D., Yan, C., Pan, X., Mahfouz, M., Wang, J., Zhu J. K., Shi, Y., and Yan, N.  (2012) Structural basis for sequence-specific recognition of DNA by TAL effectors. <I>Science</I><B>335</B>, 720-723.

Garg, A., Lohmueller, J. J., Silver, P. A. and Armel, T.Z. (2012) Engineering synthetic TAL effectors with orthogonal target sites. <I>Nucleic Acids Res.</I><B>40</B>, 7584-95.

Cong, L., Zhou, R., Kuo, Y.C., Cunniff, M., Zhang, F.(2012) Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. <I>Nat Commun.</I>3, 968.
Mak, A. N., Bradley, P., Cernadas, R. A., Bogdanove, A. J., and Stoddard, B. L. ( 2012) The crystal structure of TAL effector PthXo1 bound to its DNA target. <I>Science</I><B>335</B>, 716-719.

Miller, J. C , Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., Dulay, G. P., Hua, K. L., Ankoudinova, I., Cost, G. J., Urnov, F. D., Zhang, H. S., Holmes, M. C., Zhang, L., Gregory, P. D., and Rebar, E. J. (2011) A TALE nuclease architecture for efficient genome editing. <I>Nat. Biotechnol.</I><B>29</B>, 143-148.

Sander, J. D., Cade, L., Khayter, C., Reyon, D., Peterson, R. T., Joung, J. K., and Yeh, J.-R. J. (2011) Targeted gene disruption in somatic zebrafish cells using engineered TALENs. <I>Nat. Biotechnol.</I><B>29</B>, 697–698.

Scholze, H., and Boch, J. (2011) TAL effectors are remote controls for gene activation. <I>Curr. Opin. Microbiol.</I><B>14</B>, 47-53. 

Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G. M., and Arlotta, P. (2011) Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. <I>Nat. Biotechnol.</I><B>29</B>, 149-153.
</P><B>
Next: <A href="https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch">Mutual repressor switch &gt;&gt;</A></B></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators">http://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Slovenia/TheSwitchDesignedTALregulators" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Slovenia/TheSwitchDesignedTALregulators" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Slovenia/TheSwitchDesignedTALregulators&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Slovenia/TheSwitchDesignedTALregulators&amp;oldid=296285" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2012.igem.org:Privacy_policy" title="2012.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2012.igem.org:General_disclaimer" title="2012.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>